The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates

Rheumatology

Volumn 42, Issue 3, 2003, Pages 468-472

  Cardona, F ^b   Tinahones, F J ^b   Collantes, E ^a   Escudero, A ^a   Garcia Fuentes E ^b   Soriguer, F J ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Apolipoprotein E; Gout; Hyperuricaemia

Indexed keywords

APOLIPOPROTEIN E2; CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ALLELE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA HYBRIDIZATION; GENE AMPLIFICATION; GENOTYPE; GOUT; HUMAN; HYPERURICEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION;

ADULT; ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; GENOTYPE; GOUT; HUMANS; HYPERURICEMIA; LIPIDS; LIPOPROTEINS, VLDL; MIDDLE AGED; POLYMORPHISM, GENETIC; URIC ACID;

EID: 0345268691     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Burnier M, Brunner HR. Is hyperuricaemia a predictor of cardiovascular risk? Curr Opin Nephrol Hypertens 1999;8:167-72.
2. Collantes E, Tinahones FJ, Gonzalez A, Anon J, Pineda M, Sanchez P. Renal excretion of urate by hyperuricaemic-hyperlipidemic patients. Clin Rheumatol 1992;11:498-501.
3. Tinahones FJ, Perez G, Soriguer FJ, Pareja A, Sanchez P, Collantes E. Dietary alterations in plasma very low density lipoprotein levels modify renal excretion of urates in hyperuricemic-hypertriglyceridemic patients. J Clin Endocrinol Metab 1997;82:1188-91.
4. Shelburne F, Hanks J, Meyers W. Effect of apoproteins on hepatic uptake of triglyceride emulsion in the rat. J Clin Invest 1980;65:652-8.
5. Sherrill BC, Innerarity TL, Mahley RW. Rapid hepatic clearance of the canine lipoproteins containing only the E apoprotein by a high affinity receptor. J Biol Chem 1980;255:1804-7.
6. Innerarity TL, Mahley RW. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978;17:1440-7.
7. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Higashino K. Apolipoprotein E phenotypes in patients with gout: relation with hypertriglyceridaemia. Ann Rheum Dis 1995;54:351-3.
8. Gotto AM, Pownall HJ, Havel RJ. Introduction to the plasma lipoproteins. Methods Enzymol 1986;128:3-41.
9. Ginsberg HN. Lipoprotein physiology. Endocrinol Metab Clin North Am 1998;27:503-19.
10. Utermann G, Hess J, Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinemia in man. Nature 1977;269:604-7.
11. Zannis VI, Breslow JL, Utermann G et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982;23:911-4.
12. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30.
13. Katan MB, Beynen AC, De Vries JH, Nobels A. Existence of consistent hypo and hyperresponders to dietary cholesterol in man. Am J Epidemiol 1986;123:221-34.
14. Lopez-Miranda J, Ordovas JM, Perez-Jimenez F. Interaccion genes-dieta como determinante de las concentraciones plasmaticas de colesterol. Med Clin (Barc) 1998;111:546-51.
15. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc Natl Acad Sci USA 1989;86:6230-4.
16. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality: The NHANES I epidemiologic follow-up study, 1971-1992. J Am Med Assoc 2000;283:2404-10.
17. Burack RC, Keller JB, Higgins MW. Cardiovascular risk factors and obesity. J Chronic Dis 1985;38:865-72.
18. Nishioka K, Mikanagi K. Hereditary and environmental factors influencing on the serum uric acid throughout ten years population study in Japan. Adv Exp Med Biol 1980;122A:155-9.
19. Gutman AB, Yu TF. Gout: a derangement of purine metabolism. Adv Intern Med 1952;5:227-302.
20. Steele TH. Control of uric acid excretion. N Engl J Med 1971;284:1193-6.
21. Maclachlan MJ, Rodman GP. Effects of food, fast and alcohol on serum uric acid and acute attacks of gout. Am J Med 1967;42:38-57.
22. Lellouch J, Schwartz D, Tran MH. The relationship between smoking and levels of serum urea and uric acid. J Chronic Dis 1969;22:9-15.
23. Bonora E, Targher G, Zenere MB et al. Relationship of uric acid concentration to cardiovascular risk factors in young men: role of obesity and central fat distribution. Int J Obes Relat Metab Disord 1996;20:975-80.
24. Benedek TG. Correlations of serum uric acid and lipid concentrations in normal, gouty, and atherosclerotic men. Ann Intern Med 1967;66:851-61.
25. Tweeddale MG, Fodor JG. Elevated serum uric acid. Nephron 1979;23(Suppl. 1):3-6.
26. Steele TH, Oppenheimer S. Factors affecting urate excretion following diuretic administration in man. Am J Med 1969;47:564-74.
27. Gerhardt U, Grosse-Huttmann M, Hohage H. Influence of hyperglycemia and hyperuricemia on long-term transplant survival in kidney transplant recipients. Clin Transplant 1999;13:375-9.
28. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595.
29. Rett K, Wicklmayr M, Jacob S, Tymiec M, Dietze G, Mehnert H. Diagnostische Anhaltspunkte zur Früherkennung des metabolischen Syndroms. Munch Med Wschr 1991;133:402.
30. Ratzmann KP. Das metabolische Syndrom. Z Arztl Fortbild (Jena) 1991;85:651.
31. Darlington LG, Scott JT. Plasma lipid levels in gout. Ann Rheum Dis 1972;31:487-9.
32. BerKowitz D. Gout hyperlipidemia and diabetes inter-relationships. J Am Med Assoc 1966;197:117-20.
33. Frank O. Observations concerning the incidence of disturbance of lipid and carbohydrate metabolism in gout. Adv Exp Med Biol 1974;41:495-8.
34. Collantes E, Tinahones FJ, Cisnal A, Anon J, Sanchez P. Variability of lipid phenotypes in hyperuricaemic-hyperlipidemic patients. Clin Rheumatol 1994;13:244-7.
35. Tinahones FJ, Soriguer FJ, Collantes E, Perez-Lindon G, Sanchez P, Lillo JA. Decreased triglyceride levels with low calorie diet and increased renal excretion of uric acid in hyperuricaemic-hyperlipidaemic patients. Ann Rheum Dis 1995;54:609-10.
36. Tinahones FJ, Collantes E, Soriguer FJ et al. Increased VLDL levels and diminished renal excretion of uric acid in hyperuricaemic-hypertriglyceridaemic patients. Br J Rheumatol 1995;34:920-4.
37. Boer JMA, Ehnholm C, Menzel HJ. Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins: The EARS study. Arterioscler Thromb Vasc Biol 1997;17:1675-81.
38. Gregg RE, Brewer HB Jr. The role of apolipoprotein E and lipoprotein receptors in modulating in vivo metabolism of apolipoprotein B-containing lipoproteins in humans. Clin Chem 1988;34:B28-32.
39. Utermann G. Apolipoprotein E polymorphism in health and disease. Am Heart J 1987;113:433-40.
40. Sijbrands EJ, Westendorp RG, Hoffer MJ et al. Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis 1996;126:197-205.
41. Escola-Gil JC, Julve J, Marzal-Casacuberta A, Ordonez-Llanos J, Gonzalez-Sastre F, Blanco-Vaca F. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. J Lipid Res 2000;41:1328-38.
42. Breyer ED, Le NA, Li X, Martinson D, Brown WV. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. J Lipid Res 1999;40:1875-82.
43. Meigs JB, Ordovas JM, Cupples LA et al. Apolipoprotein E isoform polymorphisms are not associated with insulin resistance: the Framingham Offspring Study. Diabetes Care 2000;23:669-74.
44. Sijbrands EJ, Westendorp RG, Hoffer MJ et al. Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia. Arterioscler Thromb 1994;14:1576-80.
45. Sijbrands EJ, Hoffer MJ, Meinders AE et al. Severe hyperlipidemia ip apolipoprotein E2 homozygotes due to a combined effect of hyperinsulinemia and an SstI polymorphism. Arterioscler Thromb Vasc Biol 1999;19:2722-9.